The ARHGDIA Knouckout A-549 Polyclonal Cells product comprises a heterogeneous population of A-549 lung adenocarcinoma epithelial cells engineered via CRISPR/Cas9 to disrupt the ARHGDIA gene. This polyclonal knockout pool encompasses diverse editing events that collectively abolish gene function, avoiding clonal bias inherent in monoclonal derivatives. The cells provide a robust loss-of-function model tailored for investigating Rho GDP dissociation inhibitor alpha (RhoGDI??) in non-small cell lung carcinoma and are suitable for quantitative biochemical profiling, high-content imaging, and functional migration assays.
The A-549 parental line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, is a widely employed in vitro model for non-small cell lung cancer (NSCLC). These cells carry oncogenic mutations in KRAS and STK11 and retain hallmarks of alveolar type II pneumocytes, offering a clinically relevant background for studying tumorigenic signaling, drug responses, and metastatic mechanisms.
ARHGDIA encodes RhoGDI??, a master regulator that binds GDP-loaded RhoA, Rac1, and Cdc42 in the cytoplasm, inhibiting GDP dissociation and preventing GTPase activation. This suppression blocks the RhoA/ROCK/LIMK/cofilin signaling axis, maintaining a restrained actin cytoskeleton. ARHGDIA activity is modulated by upstream PI3K/AKT, SRC family kinases, and PAK, and it physically interacts with NME1 and PIP5K1A, integrating multiple signals to control cell migration.
In the A-549 context, ARHGDIA knockout is expected to disinhibit Rho GTPases, leading to constitutive actin polymerization, increased stress fiber formation, and enhanced focal adhesion turnover. These cytoskeletal changes drive accelerated migration and invasiveness, mirroring key features of metastatic dissemination. This model thus enables dissection of how RhoGDI?? deficiency promotes aggressive NSCLC tumor behavior and supports identification of anti-metastatic therapeutic targets.
Applications include western blotting for RhoA-GTP and phospho-cofilin as pathway readouts, transwell migration and Matrigel invasion assays to quantify motility, and immunofluorescence microscopy to visualize F-actin rearrangements. Quantitative Rho GTPase activation assays (G-LISA) and proliferation measurements can be integrated to explore signaling-growth interplay. For additional information or technical support, please contact Ascent Research.
